Fig. 3From: MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancerPatient outcome according to central HER2 status, MYC and MET copy numbers (CN). CN was assessed by qPCR. a, c, e survival; b, d, f time to progressionBack to article page